Open AccessResistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
Author(s) -
Jennifer A. Woyach,
Richard R. Furman,
Ta-Ming Liu,
Hatice Gülçin Özer,
Marc Zapatka,
Amy S. Ruppert,
Ling Xue,
Daniel Hsieh-Hsin Li,
Susanne Steggerda,
Matthias Versele,
Sandeep S. Davé,
Jenny Zhang,
Ayse Selen Yilmaz,
Samantha Jaglowski,
Kristie A. Blum,
Arletta Lozanski,
Gerard Lozanski,
Danelle F. James,
Jacqueline C. Barrientos,
Peter Lichter,
Stephan Stilgenbauer,
Joseph J. Buggy,
Betty Chang,
Amy J. Johnson,
John C. Byrd
Publication year - 2014
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa1400029
Subject(s) - ibrutinib , bruton's tyrosine kinase , tyrosine kinase , chronic lymphocytic leukemia , medicine , acquired resistance , lymphocytic infiltration , cancer research , tyrosine kinase inhibitor , pharmacology , leukemia , receptor , cancer
Ibrutinib is an irreversible inhibitor of Bruton's tyrosine kinase (BTK) and is effective in chronic lymphocytic leukemia (CLL). Resistance to irreversible kinase inhibitors and resistance associated with BTK inhibition have not been characterized. Although only a small proportion of patients have had a relapse during ibrutinib therapy, an understanding of resistance mechanisms is important. We evaluated patients with relapsed disease to identify mutations that may mediate ibrutinib resistance.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom